Mounjaro vs Zepbound: Comparing the Two FDA-Approved Tirzepatide Medications

Mounjaro and Zepbound both contain tirzepatide, a dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly. Despite sharing identical active ingredients, these medications carry different FDA approvals that significantly affect how they are prescribed, covered by insurance, and used in clinical practice.

Mounjaro received FDA approval in May 2022 for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise. Its approval was based on the SURPASS clinical trial program, which evaluated tirzepatide's ability to lower A1C levels and improve glycemic control. In the SURPASS-1 trial, Mounjaro reduced A1C by up to 2.07 percentage points from baseline, and patients also experienced significant weight loss as a secondary outcome.

Zepbound was approved in November 2023 specifically for chronic weight management in adults with obesity (BMI of 30 or greater) or overweight (BMI of 27 or greater) with at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea. Its approval was based on the SURMOUNT trial program, which focused on weight loss as the primary endpoint. This distinction matters because insurers and prescribers treat the two brands differently based on the diagnosed condition.

Both Mounjaro and Zepbound are administered as once-weekly subcutaneous injections using prefilled, single-dose pens. The dosing schedule and available strengths are virtually identical, reflecting the shared pharmacology of tirzepatide.

Both medications start at 2.5 mg weekly for four weeks as an initiation dose. After this period, the dose increases to 5 mg weekly. From there, dose escalation occurs in 2.5 mg increments every four weeks based on tolerability and clinical response. Both Mounjaro and Zepbound are available in six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.

The maximum dose for both brands is 15 mg per week. In clinical trials, higher doses generally produced greater effects — whether measured by A1C reduction (for Mounjaro/diabetes) or weight loss (for Zepbound/obesity). In the SURMOUNT-1 trial, participants on 15 mg Zepbound lost an average of 22.5% of body weight, while in SURPASS-2, patients on 15 mg Mounjaro achieved A1C reductions of approximately 2.45 percentage points. Clinicians typically titrate to the dose that provides adequate clinical benefit while maintaining tolerability.

The most consequential difference between Mounjaro and Zepbound lies in insurance coverage, which is directly tied to their FDA-approved indications. This distinction frequently determines which brand patients can access and at what cost.

Mounjaro, as a diabetes medication, is covered by the vast majority of commercial insurance plans, Medicare Part D, and Medicaid programs. Most plans require a prior authorization confirming a diagnosis of type 2 diabetes, and some require documentation that the patient has tried metformin or another first-line agent before approving tirzepatide. Once approved, copays typically range from $25 to $150 per month, depending on the formulary tier.

Zepbound coverage for weight management is significantly more limited. As of early 2025, only about 40% of commercial insurance plans cover anti-obesity medications, and many that do impose stricter criteria. Medicare historically excluded coverage for weight loss drugs, though recent legislative changes are beginning to expand access. Eli Lilly offers a savings card for commercially insured patients that can reduce Zepbound copays to as little as $25 per month for eligible individuals, though patients on government insurance programs do not qualify.

Some clinicians prescribe Mounjaro off-label for weight loss in patients without diabetes, but insurance rarely covers this use. Patients seeking weight management without a diabetes diagnosis often face the full retail cost or turn to alternatives like compounded tirzepatide.

Because Mounjaro and Zepbound contain the same active ingredient at the same doses, their side effect profiles are essentially identical. The most commonly reported adverse effects are gastrointestinal in nature, consistent with the pharmacology of GLP-1 receptor agonists.

In clinical trials for both brands, the most frequent side effects included nausea (occurring in 12-18% of participants depending on dose), diarrhea (12-17%), decreased appetite (10-14%), vomiting (5-9%), constipation (5-7%), dyspepsia (5-8%), and abdominal pain (5-6%). These effects are generally mild to moderate, occur most frequently during dose escalation, and tend to diminish over time as the body adjusts.

Both medications carry the same boxed warning regarding medullary thyroid carcinoma (MTC), based on findings in rodent studies. They are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Both are also not recommended for patients with a history of pancreatitis.

Serious but rare adverse events reported with tirzepatide include acute pancreatitis, acute gallbladder disease, and hypoglycemia (primarily when used with insulin or sulfonylureas). The overall safety profile established across the SURPASS and SURMOUNT programs — encompassing more than 10,000 participants — shows that tirzepatide is generally well tolerated, with most patients able to continue treatment through dose escalation.

Understanding the cost landscape for Mounjaro and Zepbound helps patients make informed decisions. Both medications carry substantial retail prices that reflect their status as branded, patented pharmaceuticals.

Mounjaro's wholesale acquisition cost is approximately $1,023 per month, and the retail cash price at most pharmacies falls between $1,000 and $1,100 per month. Zepbound is priced slightly higher at approximately $1,060 per month retail. Without insurance or manufacturer savings programs, these costs represent a significant financial commitment.

For patients with commercial insurance coverage for Mounjaro (diabetes indication), out-of-pocket costs can drop substantially. Eli Lilly's savings card programs can further reduce copays. However, for patients seeking tirzepatide specifically for weight management — particularly those without diabetes — insurance coverage is unreliable and brand-name costs are prohibitive for many households.

Compounded tirzepatide offers a more accessible alternative. Produced by 503A and 503B compounding pharmacies under FDA oversight, compounded versions typically cost between $300 and $500 per month. At Weight Method, we offer tirzepatide subscriptions starting at $349 per month. This includes the medication, prescriber evaluation, dosing management, and ongoing clinical support. Our medical team determines whether tirzepatide is appropriate based on your health profile, BMI, and treatment goals — regardless of which brand indication you might have pursued through traditional channels.